Form 4: Jazz Pharmaceuticals Executive Neena Patil Reports Share Transactions Following Performance Award Vesting

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena Patil, acquired shares following the vesting of performance awards and sold shares to cover tax obligations.

Summary

• Neena Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals, reported transactions involving ordinary shares.
• On January 17, 2025, Ms. Patil acquired 5,864 ordinary shares as part of a performance share award that vested.
• The performance-based vesting requirements for these awards were met on January 17, 2025.
• Additionally, 1,905 shares were disposed of on the same day at a price of $122.62 per share to cover tax obligations related to the vesting.
• Ms. Patil also acquired 111 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024.
• Following these transactions, Ms. Patil beneficially owns 37,118 ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of performance awards suggests the company is meeting its goals, while the sale of shares for tax purposes is a normal occurrence.

Positives

• The vesting of performance share awards indicates that performance goals were met, which is a positive sign for the company.
• The acquisition of shares through the employee stock purchase plan shows Ms. Patil's continued investment in the company.

Negatives

• The sale of 1,905 shares to cover tax obligations, while standard, does reduce Ms. Patil's overall holdings.

Risks

• There are no specific risks mentioned in this document, as it primarily details share transactions.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders conduct transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The share transactions are typical for executives at publicly traded companies, especially following the vesting of performance-based awards.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies such as AbbVie, Amgen, and Gilead Sciences.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The vesting of performance awards may be viewed positively by shareholders as it indicates the company is meeting its performance targets.

Key Dates

Keywords

Jazz Pharmaceuticals, Neena Patil, share transactions, performance awards, vesting, insider trading, stock purchase plan, tax obligations